Headlines about Regulus Therapeutics (NASDAQ:RGLS) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.510832469585 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

RGLS has been the subject of several recent research reports. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Wednesday, July 12th. Chardan Capital lowered shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the company a “hold” rating in a research report on Monday, June 12th. ValuEngine lowered shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $3.63.

Regulus Therapeutics (RGLS) traded up 3.05% during mid-day trading on Monday, reaching $1.35. 850,144 shares of the company traded hands. The firm’s market capitalization is $140.11 million. The stock’s 50 day moving average price is $1.01 and its 200 day moving average price is $1.23. Regulus Therapeutics has a 52 week low of $0.79 and a 52 week high of $3.65.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. Equities analysts forecast that Regulus Therapeutics will post ($1.02) EPS for the current year.

In related news, Director William H. Rastetter purchased 274,725 shares of the stock in a transaction dated Tuesday, July 25th. The shares were acquired at an average cost of $0.91 per share, with a total value of $249,999.75. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniel R. Chevallard purchased 54,945 shares of the stock in a transaction dated Tuesday, July 25th. The shares were bought at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the completion of the purchase, the chief financial officer now owns 59,415 shares in the company, valued at $54,067.65. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 549,450 shares of company stock valued at $500,000. 4.80% of the stock is owned by insiders.

WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/25/regulus-therapeutics-rgls-receives-coverage-optimism-score-of-0-14.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.